BACKGROUND AND AIM: Chronic obstructive pulmonary disease (COPD) is a serious disease with morbidity and mortality due to delayed diagnosis until significant symptoms arise. We aimed to assess the utility of spirometry and COPD Assessment Test (CAT) in detecting undiagnosed COPD patients in a localized area. MATERIAL AND METHODS: People who came to the hospital for patient visit or examination with a smoking history of > 10 pack-years (> 40 years old), and with no known chest disease were invited to study. The participants completed a questionnaire and performed spirometry. Spirometry was performed according to ATS/ERS Task Force on spirometry. COPD was defined as according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. RESULTS: There were 800 subjects screened, and 648, capable of performing spirometry, were included to the study. The mean age was 48.3 ± 9.0 and 38 % of the study population was male. Post-bronchodilator FEV1/FVC ratio was lower than 0.70 in 17 % of the subjects. Median (25-75 percentiles) total CAT scores and among the questions of CAT; cough, phlegm, chest tightness and breathlessness scores for COPD and non-COPD subjects were; 15(9-22) vs 12(6-18) (p = .004), 2(1-3) vs 1(0-2) (p < .001), 2(0-3) vs 1(0-3) (p = .004), 3(1-4) vs 2(0-3) (p > .001), 4(3-5) vs 3(2-4) (p = .001), respectively. Symptom prevalence was as follows: exertional dyspnea 91 %, dyspnea 80.9 %, cough 56.3 % and phlegm 58.3 % in COPD. CONCLUSION: Our study showed that spirometric screening together with the CAT questionnaire may improve the awareness of disease and may determine undiagnosed patients.
BACKGROUND AND AIM: Chronic obstructive pulmonary disease (COPD) is a serious disease with morbidity and mortality due to delayed diagnosis until significant symptoms arise. We aimed to assess the utility of spirometry and COPD Assessment Test (CAT) in detecting undiagnosed COPDpatients in a localized area. MATERIAL AND METHODS:People who came to the hospital for patient visit or examination with a smoking history of > 10 pack-years (> 40 years old), and with no known chest disease were invited to study. The participants completed a questionnaire and performed spirometry. Spirometry was performed according to ATS/ERS Task Force on spirometry. COPD was defined as according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. RESULTS: There were 800 subjects screened, and 648, capable of performing spirometry, were included to the study. The mean age was 48.3 ± 9.0 and 38 % of the study population was male. Post-bronchodilator FEV1/FVC ratio was lower than 0.70 in 17 % of the subjects. Median (25-75 percentiles) total CAT scores and among the questions of CAT; cough, phlegm, chest tightness and breathlessness scores for COPD and non-COPD subjects were; 15(9-22) vs 12(6-18) (p = .004), 2(1-3) vs 1(0-2) (p < .001), 2(0-3) vs 1(0-3) (p = .004), 3(1-4) vs 2(0-3) (p > .001), 4(3-5) vs 3(2-4) (p = .001), respectively. Symptom prevalence was as follows: exertional dyspnea 91 %, dyspnea 80.9 %, cough 56.3 % and phlegm 58.3 % in COPD. CONCLUSION: Our study showed that spirometric screening together with the CAT questionnaire may improve the awareness of disease and may determine undiagnosed patients.
Authors: A Sonia Buist; William M Vollmer; Sean D Sullivan; Kevin B Weiss; Todd A Lee; Ana M B Menezes; Robert O Crapo; Robert L Jensen; Peter G J Burney Journal: COPD Date: 2005-06 Impact factor: 2.409
Authors: M Bednarek; D Gorecka; J Wielgomas; M Czajkowska-Malinowska; J Regula; G Mieszko-Filipczyk; M Jasionowicz; R Bijata-Bronisz; M Lempicka-Jastrzebska; M Czajkowski; G Przybylski; J Zielinski Journal: Thorax Date: 2006-06-29 Impact factor: 9.139
Authors: P W Jones; G Brusselle; R W Dal Negro; M Ferrer; P Kardos; M L Levy; T Perez; J J Soler Cataluña; T van der Molen; L Adamek; N Banik Journal: Eur Respir J Date: 2011-05-12 Impact factor: 16.671
Authors: A Sonia Buist; Mary Ann McBurnie; William M Vollmer; Suzanne Gillespie; Peter Burney; David M Mannino; Ana M B Menezes; Sean D Sullivan; Todd A Lee; Kevin B Weiss; Robert L Jensen; Guy B Marks; Amund Gulsvik; Ewa Nizankowska-Mogilnicka Journal: Lancet Date: 2007-09-01 Impact factor: 79.321
Authors: W M Vollmer; Thorn Gíslason; P Burney; P L Enright; A Gulsvik; A Kocabas; A S Buist Journal: Eur Respir J Date: 2009-05-21 Impact factor: 16.671
Authors: Karin D Eikhof; Kristine R Olsen; N C H Wrengler; Carl Nielsen; Uffe Bodtger; Ingrid L Titlestad; Ulla M Weinreich Journal: Eur Clin Respir J Date: 2017-03-08
Authors: Georgios Ntritsos; Jacob Franek; Lazaros Belbasis; Maria A Christou; Georgios Markozannes; Pablo Altman; Robert Fogel; Tobias Sayre; Evangelia E Ntzani; Evangelos Evangelou Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-05-10
Authors: Igor Larchert Mota; Antônio Carlos Sobral Sousa; Maria Luiza Doria Almeida; Enaldo Vieira de Melo; Eduardo José Pereira Ferreira; José Barreto Neto; Carlos José Oliveira Matos; Caio José Coutinho Leal Telino; Maria Júlia Silveira Souto; Joselina Luzia Menezes Oliveira Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-06-26
Authors: Ivan P Artyukhov; Irina L Arshukova; Elena A Dobretsova; Tatyana A Dugina; Andrey V Shulmin; Irina V Demko Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-09-02
Authors: Bassam H Mahboub; Mayank Gian Vats; Ashraf Al Zaabi; Mohammed Nizam Iqbal; Tarek Safwat; Fatma Al-Hurish; Marc Miravitlles; Dave Singh; Khaled Asad; Salah Zeineldine; Mohamed S Al-Hajjaj Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-10-09